David Olson

Delix Therapeutics recently published findings from a study about the mechanism that causes psychoplastogens and serotonin to activate the 5-HT2A receptor in different ways.  The paper, developed in collaboration with researchers at UC-Davis, offers unprecedented insight into the long-standing...

Delix Therapeutics, a drug development company in the psychedelics space, has closed a $70 million Series A financing round. The Boston-based company became known in the medicinal psychedelics space for developing a subset of psychedelic molecules that could have some of the therapeutic effects of...

A new study published in the peer-review journal Cell looks at a novel compound capable of providing some of the therapeutic properties of psychedelics without hallucinations. The paper, co-authored by Delix Therapeutics co-founder and chief scientific officer David Olson, Ph.D.,...